Wanda has developed a system which continuously assesses patients in real time and can detect adverse events up to a week before they happen.
By using that technology, the number of hospital readmissions for congestive heart failure patients – a patient population with a typically high readmission rate – almost halved (46% reduction).
There are currently 576 patients enrolled on the programme, but Martelet, who is also chairman of Wanda, thinks the latest figures provide a “strong rationale” for rolling out the system to more people.
“The data are impressive as patients with congestive heart failure typically have a very high re-admission rate,” said Martelet.
“This demonstrates the invaluable potential Wanda's technology has in streamlining care and improving patient outcomes.”
He added: “We are entering a new digital era of healthcare in which we firmly believe Wanda can play a pivotal role, and we are very pleased to see the collaboration with HRS working so well.”
NetScientific holds a 62% stake in Wanda.
Shares rose 12.6% to 49p at the opening bell on Monday.
--Updates for share price--